AKYA · NASDAQ
Price unavailable right now.
This isn't available right now. Refresh to try again.
Updated May 8, 2025
Akoya Biosciences, Inc. posted a revenue of $21.3 million for 4Q24, aligning with consensus expectations, despite a challenging operating environment. The company demonstrated strong operational efficiency with a gross margin of 67.4%, surpassing both internal and consensus estimates. With a solid cash balance of $35.7 million and an expanding install base of 1,330 instruments, Akoya is well-positioned to capitalize on growth opportunities in the spatial biology market.
Akoya Biosciences Inc. faces a negative outlook due to its reliance on government and private funding, which is experiencing a tightening, potentially stifling growth prospects. The company has not achieved profitability and has consistently burned cash, raising concerns about its financial sustainability, particularly in a competitive landscape where superior alternatives could diminish its market share. Additionally, regulatory risks and susceptibility to macro sentiment shifts further exacerbate the challenges, as failure to secure adequate cash levels may jeopardize operational viability.
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.
